Nomad Foods is set to close its Rorschach manufacturing facility in Switzerland by year-end as part of the European frozen-food group’s cost-saving strategy. This decision is in line with the company’s “long-term productivity programme” announced last year.
The UK-based owner of the Birds Eye, Iglo, and Findus brands stated that the planned closure would impact 45 full-time employees, with consultations scheduled to run until May 8.
As indicated in September, Nomad Foods is targeting €200 million ($233.1 million) in operational savings during its 2026 to 2028 financial years. The company anticipates achieving efficiencies in procurement, logistics, and overhead costs. Notably, the main savings will stem from a procurement transformation program aimed at enhancing overall performance.
Alongside this, Nomad Foods seeks to improve resource utilization throughout its manufacturing network, reduce logistics expenses, and identify overhead efficiencies. The company believes these measures will enable it to make “targeted reinvestments” while addressing inflationary pressures in the food and beverage industry.
Production currently handled at Rorschach, which includes frozen meals like Plätzli, lasagna, and cannelloni marketed under the Findus brand in Switzerland, will be shifted to other facilities in Italy and Spain. Eduardo Bachiega, Nomad Foods’ chief supply officer, remarked, “This is a very difficult decision and over the coming months we will work closely with all affected employees to provide support throughout this transition.”
Importantly, the company assured that supply to the Swiss market would remain uninterrupted amid these changes. This announcement comes as Nomad Foods navigates a challenging trading landscape.
Recently, chief executive Dominic Brisby, who assumed leadership in January, characterized this period as a “transition year,” signaling “some near-term turbulence.” In 2025, the company’s organic sales declined by 1.9% to €3 billion, with both volume and price/mix experiencing dips. Reported revenue fell by 2.2%, and the outlook for 2026 suggests a further organic sales decline of 2-5%.
Looking ahead, adjusted EBITDA forecasts show a potential decline of 5-10%, following a 7.5% decrease in 2025. Additionally, adjusted EPS is projected to drop by 4-13%, compared to a previous decline of 6.7% last year.
